Biogen Idec Ma Inc.

Janssen Pharmaceutica Nv

Tibotec Pharmaceuticals Ltd.

Biogen Ma Inc.

Herman Van Vlijmen

Alexey Alexandrovich Lugovskoy

Jose William Saldanha

Ellen A Garber

Karl Hanf

Antonin De Fougerolles

Victor E Kotelianski

Kenneth J Simon

Carl Reid

You Li

Jean-François Bonfanti

Scott Glaser

Eric Pierre Alexandre Arnoult

Michele Sanicola-Nadel

Xiufeng Wu

Karl J M Hanf

Jörg Kurt Wegner

Dirk André Emmy Roymans

Alexey Alexandrovic Lugovskoy

Carlo Willy Maurice Boutton

Hendrik Leon Augusta Jozef De Bondt

Louise A Koopman

The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.

Anti-CD154 antibodies

The invention concerns the generation of a three dimensional model of the six helix bundle (6HB) complexed with an inhibitor and the use of that model to identify, screen and/or develop inhibitors against viruses that use a class I fusion protein. Such inhibitors of viruses that use a class I fusion protein may be effective for treating, for example, respiratory infections by Respiratory Syncytial Virus (RSV).

Methods for identifying inhibitors against viruses that use a class I fusion protein

The invention provides humanized antibodies that bind to a plurality of &#x3b2;-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.

Humanized antibodies against monocyte chemotactic proteins

The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues

The present invention relates to methods and systems for predicting the phenotype conferred by a protein. Such methods and systems facilitate the design, optimization, and assessment of the efficiency of a therapeutic regimen based on the genotype of the disease affecting the patient.

Phenotype prediction method

The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.

Cripto binding molecules

The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.

Humanized antibodies against monocyte chemotactric proteins

Growing community of inventors

Mechelen, Belgium

Herman Van Vlijmen